Retifanlimab
Retifanlimab regimen improves outcomes in advanced anal cancer
The addition of retifanlimab to standard first-line chemotherapy improved outcomes for certain patients with advanced squamous cell carcinoma of the anal canal, according to randomized phase 3 study results presented at ESMO Congress.
FDA grants accelerated approval to Zynyz for metastatic, recurrent Merkel cell carcinoma
The FDA granted accelerated approval to retifanlimab-dlwr for treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
FDA issues complete response letter for retifanlimab for anal cancer
Advisory panel recommends FDA defer decision on retifanlimab for anal cancer subset
FDA’s Oncologic Drugs Advisory Committee today voted 13 to 4 to recommend deferral of a regulatory decision on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal.
FDA grants priority review to retifanlimab for anal cancer subset
The FDA granted priority review to retifanlimab for treatment of certain patients with squamous cell carcinoma of the anal canal, according to the agent’s manufacturer.